



Immune Response and Vaccines for SARS-CoV-2 Infection

Guest Editor:

Dr. Shumaila Hanif

Department of Biomedical
Sciences, University of Pikeville,
Coal Building, Office 718, 147
Sycamore Street, Pikeville, KY
41501, USA

Deadline for manuscript
submissions:

closed (30 June 2023)

Message from the Guest Editor

With the recent COVID-19 pandemic, much research has been conducted on this topic "Immune Response and Vaccines for SARS-CoV-2 Infection". While mRNA has been studied since the 1990s, in recent years, mRNA has generated significant excitement for human use despite the licensure of several veterinary DNA vaccines. Recently, Pfizer and Moderna launched an mRNA vaccine for SARS-CoV-2, which has been administered to people across the globe. DNA and RNA vaccines are faster and cheaper to produce in large quantities than conventional vaccines. On the other hand, conventional vaccines often use "weakened" or "killed" versions of a virus, meaning that laboratories need to produce huge amounts of the virus. They often also include a protein, which is needed to spark a human immune response. However, producing a virus and a viral protein can be time-intensive and expensive. Therefore, this Special Issue will serve as a forum where scientists can share their latest research findings on the immune responses and vaccines related to infectious diseases, particularly SARS-CoV-2.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com